Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-262P is a pseudogene of the U6 small nuclear RNA (snRNA) gene family. Unlike canonical U6 snRNAs, which are essential for the spliceosome-mediated splicing of pre-mRNA, pseudogenes such as RNU6-262P are nonfunctional genomic elements generated through retrotransposition events, often involving LINE elements[4]. U6 snRNAs are highly conserved and function as part of the catalytic core of the spliceosome, but pseudogenes (like RNU6-262P) lack the necessary regulatory sequences or structural integrity to produce functional RNA products[1][4]. U6 snRNA pseudogenes can serve as markers of retrotransposition activity in the genome but are not known to have direct biological functions, disease associations, or therapeutic relevance[4]. There is no evidence that RNU6-262P is a protein, functional enzyme, receptor, or that it modulates any signaling, metabolic, or pathological process[4]. Pseudogenes in general may occasionally impact gene regulation (e.g., acting as competitive endogenous RNAs), but there is no direct evidence that RNU6-262P fulfills such a role[2]. Key context: RNU6-262P is a pseudogene, not an active molecular target, therapeutic target, or biomarker. Its presence in the genome reflects the history of retrotransposition events rather than biological activity[4]. There are no known drugs, mechanisms of action, or diseases associated with RNU6-262P. It should not be listed as a canonical molecular target in drug discovery or biomedical contexts. Errors/Concerns: This entry is not a misspelling, but it does not correspond to an active molecular target. Use is_target: false for structured curation. If a canonical functional form is needed, then U6 small nuclear RNA (RNU6-2) would be the active (non-pseudogene) form[3]. Summary for database structuring: This entry represents a nonfunctional RNA pseudogene; it should not be regarded as a molecular therapeutic target or a receptor/enzyme/transporter.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 262, pseudogene (RNU6-262P).